Clinical Trials Logo

Autism Spectrum Disorder (ASD) clinical trials

View clinical trials related to Autism Spectrum Disorder (ASD).

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03715166 Terminated - Clinical trials for Autism Spectrum Disorder (ASD)

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder

Start date: September 24, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacy and the safety of bumetanide/S95008 in the improvement of Autism Spectrum Disorder core symptoms.

NCT ID: NCT03715153 Terminated - Clinical trials for Autism Spectrum Disorder (ASD)

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.

Start date: October 4, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the efficacity and the safety of bumetanide/S95008 in the improvement of Autism Spectrum Disorder core symptoms.

NCT ID: NCT01592773 Terminated - Autism Clinical Trials

Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

Start date: October 2012
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the long-term safety and tolerability of memantine in the treatment of pediatric patients with autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).

NCT ID: NCT01248130 Terminated - Clinical trials for Autism Spectrum Disorder (ASD)

Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders

Start date: November 2009
Phase: Phase 2
Study type: Interventional

The primary aim of this study is to examine the efficacy and tolerability of short-term omega-3 fatty acids monotherapy in youth with Autism Spectrum Disorders (ASD). The investigators hypothesize that Omega-3 fatty acids will be efficacious in improving the core and associated features of ASD in youth, and that Omega-3 fatty acids monotherapy will be safe and well tolerated by youth with ASD. The secondary aim of this study is to examine the neuropsychological effect of Omega-3 fatty acids monotherapy in youth with ASD. The investigators hypothesize that omega-3 fatty acids will be efficacious in improving cognitive functions in youth with ASD.